Drug Stock Soars on China Pharma Manufacturing Deal

The deal will allow for manufacturing of two key CASI drugs in China

Jun 21, 2018 at 9:28 AM
facebook twitter linkedin


CASI Pharmaceuticals Inc (NASDAQ:CASI) said it's teamed up with China-based Yiling Wanzhou International Pharmaceutical Co. to manufacture entecavir and cilostazol, which are used to treat hepatitis B and blood flow, respectively. In reaction, CASI stock is 38% in electronic trading, set to open near its mid-May highs.

Last night, CASI shares closed at $5.70 -- up more than 75% year-to-date. However, the stock had shed 32% since its May 4 seven-year high of $8.42, and had recently been testing support at its 80-day moving average.

Short sellers could feel pressured to cover, should the stock gap higher. Short interest jumped 24% in the most recent reporting period to 2.11 million shares -- representing almost 8% of CASI Pharmaceuticals stock's float, or 5.5 times the average pace of trading.

Cantor Fitzgerald reiterated its "overweight" rating and $23 price target on Mesoblast Limited (NASDAQ:MESO) -- a 315% premium to last night's close at $5.54, and a level not surpassed since September 2014. The brokerage firm waxed optimistic on the Australia-based stem cell specialist's data on its treatment for children with steroid-refractory acute graft versus host disease (aGVHD), saying there were "no surprises" in the results for the late-stage study.

Against this backdrop, MESO stock is up 17.3% in electronic trading. It's been a volatile 12 months for the shares, which were trading as high as $8.55 last July, and as low as $4.74 in February. After topping out at a year-to-date peak near $7.80 in early March, the shares have spent the past three months chopping between $5.25 and $6.50.

While the majority of analysts are staunchly supportive of Mesoblast -- five of six maintain a "strong buy" recommendation -- short sellers have started ramping up their exposure. Short interest surged 26.4% in the most recent reporting period to around 80,000 shares, the most since mid-March. This still just accounts for a low 0.1% of the equity's available float, though.

 

Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 

 


 


 
Special Offers from Schaeffer's Trading Partners